Iqvia Holdings (IQV) | Financial Analysis & Statements
Iqvia Holdings Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
4.4B
Gross Profit
1.4B
32.91%
Operating Income
651.0M
14.92%
Net Income
514.0M
11.78%
EPS (Diluted)
$2.99
Balance Sheet Metrics
Total Assets
29.9B
Total Liabilities
23.3B
Shareholders Equity
6.6B
Debt to Equity
3.52
Cash Flow Metrics
Operating Cash Flow
912.0M
Free Cash Flow
772.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Iqvia Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 16.3B | 15.4B | 15.0B | 14.4B | 13.9B |
| Cost of Goods Sold | 10.9B | 10.0B | 9.7B | 9.4B | 9.2B |
| Gross Profit | 5.4B | 5.4B | 5.2B | 5.0B | 4.6B |
| Gross Margin % | 33.3% | 34.9% | 35.0% | 34.9% | 33.5% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 2.0B | 2.0B | 2.1B | 2.1B | 2.0B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 2.0B | 2.0B | 2.1B | 2.1B | 2.0B |
| Operating Income | 2.3B | 2.3B | 2.1B | 1.8B | 1.4B |
| Operating Margin % | 14.0% | 14.7% | 13.8% | 12.7% | 10.2% |
| Non-Operating Items | |||||
| Interest Income | 45.0M | 47.0M | 36.0M | 13.0M | 6.0M |
| Interest Expense | 729.0M | 670.0M | 672.0M | 416.0M | 375.0M |
| Other Non-Operating Income | -12.0M | 23.0M | 34.0M | -61.0M | 84.0M |
| Pre-tax Income | 1.6B | 1.7B | 1.5B | 1.4B | 1.1B |
| Income Tax | 252.0M | 301.0M | 101.0M | 260.0M | 163.0M |
| Effective Tax Rate % | 15.8% | 18.0% | 6.9% | 19.1% | 14.5% |
| Net Income | 1.4B | 1.4B | 1.4B | 1.1B | 971.0M |
| Net Margin % | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% |
| Key Metrics | |||||
| EBITDA | 3.6B | 3.5B | 3.3B | 2.9B | 2.8B |
| EPS (Basic) | $7.91 | $7.57 | $7.39 | $5.82 | $5.05 |
| EPS (Diluted) | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 |
| Basic Shares Outstanding | 171900000 | 181300000 | 183800000 | 187600000 | 191400000 |
| Diluted Shares Outstanding | 171900000 | 181300000 | 183800000 | 187600000 | 191400000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Iqvia Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 2.0B | 1.7B | 1.4B | 1.2B | 1.4B |
| Short-term Investments | 161.0M | 141.0M | 120.0M | 93.0M | 111.0M |
| Accounts Receivable | 1.7B | 1.4B | 1.5B | 1.3B | 1.3B |
| Inventory | - | - | - | - | - |
| Other Current Assets | 519.0M | 592.0M | 546.0M | 561.0M | 521.0M |
| Total Current Assets | 6.2B | 5.8B | 5.6B | 5.0B | 4.8B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.6B | 1.4B | 1.5B | 1.5B | 1.5B |
| Goodwill | 38.2B | 33.9B | 34.0B | 32.7B | 31.5B |
| Intangible Assets | 5.0B | 4.5B | 4.8B | 4.8B | 4.9B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 862.0M | 714.0M | 621.0M | 590.0M | 615.0M |
| Total Non-Current Assets | 23.7B | 21.1B | 21.1B | 20.4B | 19.9B |
| Total Assets | 29.9B | 26.9B | 26.7B | 25.3B | 24.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 780.0M | 736.0M | 709.0M | 645.0M | 621.0M |
| Short-term Debt | 1.8B | 1.1B | 718.0M | 152.0M | 91.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 489.0M | 193.0M | 294.0M | 152.0M | 207.0M |
| Total Current Liabilities | 8.3B | 7.0B | 6.5B | 5.6B | 5.2B |
| Non-Current Liabilities | |||||
| Long-term Debt | 14.1B | 13.0B | 13.2B | 12.9B | 12.3B |
| Deferred Tax Liabilities | 179.0M | 196.0M | 202.0M | 464.0M | 410.0M |
| Other Non-Current Liabilities | 688.0M | 668.0M | 698.0M | 671.0M | 649.0M |
| Total Non-Current Liabilities | 15.0B | 13.9B | 14.1B | 14.0B | 13.4B |
| Total Liabilities | 23.3B | 20.8B | 20.6B | 19.6B | 18.6B |
| Equity | |||||
| Common Stock | 3.0M | 3.0M | 11.0B | 10.9B | 3.0M |
| Retained Earnings | 7.4B | 6.1B | 4.7B | 3.3B | 2.2B |
| Treasury Stock | 11.4B | 10.1B | 8.7B | 7.7B | 6.6B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.6B | 6.1B | 6.1B | 5.8B | 6.0B |
| Key Metrics | |||||
| Total Debt | 15.9B | 14.2B | 13.9B | 13.0B | 12.4B |
| Working Capital | -2.1B | -1.1B | -895.0M | -597.0M | -478.0M |
Balance Sheet Composition
Iqvia Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.4B | 1.4B | 1.4B | 1.1B | 971.0M |
| Depreciation & Amortization | 1.1B | 1.1B | 1.1B | 1.1B | 1.3B |
| Stock-Based Compensation | 247.0M | 206.0M | 217.0M | 194.0M | 170.0M |
| Working Capital Changes | 206.0M | 306.0M | -150.0M | 37.0M | 697.0M |
| Operating Cash Flow | 2.8B | 2.9B | 2.3B | 2.4B | 3.0B |
| Investing Activities | |||||
| Capital Expenditures | -528.0M | -577.0M | -649.0M | -674.0M | -640.0M |
| Acquisitions | -1.8B | -867.0M | -915.0M | -1.3B | -1.5B |
| Investment Purchases | -20.0M | -2.0M | -44.0M | -5.0M | -10.0M |
| Investment Sales | 2.0M | - | - | 0 | 5.0M |
| Investing Cash Flow | -2.3B | -1.4B | -1.6B | -2.0B | -2.1B |
| Financing Activities | |||||
| Share Repurchases | -1.2B | -1.4B | -992.0M | -1.2B | -406.0M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 9.8B | 1.7B | 4.0B | 1.2B | 2.0B |
| Debt Repayment | -8.6B | -1.1B | -5.6B | -2.7B | -2.7B |
| Financing Cash Flow | -83.0M | -814.0M | -3.0B | -2.3B | -1.8B |
| Free Cash Flow | 2.1B | 2.1B | 1.5B | 1.6B | 2.3B |
| Net Change in Cash | 413.0M | 633.0M | -2.3B | -1.9B | -898.0M |
Cash Flow Trend
Iqvia Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
22.38
Forward P/E
12.44
Price to Book
4.57
Price to Sales
1.82
PEG Ratio
0.94
Profitability Ratios
Profit Margin
8.34%
Operating Margin
15.17%
Return on Equity
21.44%
Return on Assets
5.05%
Financial Health
Current Ratio
0.75
Debt to Equity
245.93
Beta
1.39
Per Share Data
EPS (TTM)
$7.83
Book Value per Share
$38.34
Revenue per Share
$94.88
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IQV | 27.3B | 22.38 | 4.57 | 21.44% | 8.34% | 245.93 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.






